{
    "nct_id": "NCT04240808",
    "official_title": "Phase I Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)",
    "inclusion_criteria": "* Provision of signed and dated Informed Consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the parent study and the long-term follow-up observational study.\n* Male or non-pregnant, non-lactating females, aged 18 to 80 years.\n* Performance status according to the Eastern Cooperative Oncology Group â‰¤ 2.\n* Failed two or more lines of systemic therapy.\n* Unable to receive commercially available CD19 CAR T Cells.\n* Relapsed or primary refractory CD19 positive (i.e. CD19 expressing) B-NHL of the following types as confirmed by either flow cytometry, Immunohistochemistry (IHC), or both:\n\n  * Diffuse large B-cell lymphoma (DLBCL)\n  * Burkitt lymphoma\n  * Intermediate lymphoma between Burkitt and DLBCL\n  * Primary Mediastinal B-cell lymphoma (PMBL)\n  * Follicular lymphoma\n  * Mantle cell lymphoma (MCL)\n  * Marginal zone lymphoma (MZL)\n* No available curative alternative treatment, as determined by primary treating oncologist.\n* No active Graft-versus-Host Disease (GvHD).\n* In women of childbearing potential, willingness to use effective means of birth control for 1 year after UCD19 CAR T Cell infusion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Prior therapies:\n\n  * Received monoclonal antibody therapy within 14 days of the apheresis; or\n  * Received immunomodulatory drugs (lenalidomide, tyrosine kinase inhibitors) within 14 days of the apheresis; or\n  * Received corticosteroids more than 7.5mg/day within 14 days of the apheresis (physiologic replacement allowed up until apheresis, as clinically indicated); or\n  * Allogeneic hematopoietic stem cell transplant with 90 days (immunosuppressive therapy for at least 4 weeks) of apheresis; or\n  * Donor lymphocyte infusion within 4 weeks of apheresis.\n  * Cluster of differentiation 3 (CD3) count <0.15 x 106 cells/mL\n* Severe psychiatric illness that could impede the patient's ability to provide informed consent and/or adhere to the parent protocol and/or the long-term follow-up protocol.\n* Active HIV (Acquired Immune Deficiency Syndrome) or history of HIV infection, as directed by schedule or if known.\n* Active Hepatitis B or Hepatitis C infection.\n* Diffusion capacity of the lungs for carbon monoxide < 40% predicted prior to lymphodepletion.\n* Left ventricular ejection fraction < 40% (evaluated by echocardiogram [ECHO] or Multigated Acquisition Scan [MUGA]) prior to lymphodepletion.\n* Transaminases > 5x upper limit of normal prior to lymphodepletion.\n* Serum Bilirubin > 4 mg/dL prior to lymphodepletion.\n* Serum Creatinine > 1.6 mg/dL or measured creatinine clearance < 50 mL/min prior to lymphodepletion.\n* Active infection that is unresponsive to antimicrobial therapy prior to lymphodepletion.\n* Females planning to become pregnant during the course of the study.\n* Unwillingness or inability to comply with study visits and study procedures for the entire duration of study participation.\n* Unsuitable for cellular therapy for any reason, in the opinion of the Investigator.\n* Any prior gene therapy, including prior CAR T cell therapy.\n* Active central nervous system (CNS) disease.",
    "miscellaneous_criteria": ""
}